Caplin Point Laboratories (BOM:524742) COGS-to-Revenue : 0.40 (As of Jun. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Caplin Point Laboratories COGS-to-Revenue?

Caplin Point Laboratories's Cost of Goods Sold for the three months ended in Jun. 2024 was ₹1,855 Mil. Its Revenue for the three months ended in Jun. 2024 was ₹4,590 Mil.

Caplin Point Laboratories's COGS to Revenue for the three months ended in Jun. 2024 was 0.40.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Caplin Point Laboratories's Gross Margin % for the three months ended in Jun. 2024 was 59.59%.

Caplin Point Laboratories COGS-to-Revenue Historical Data

The historical data trend for Caplin Point Laboratories's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caplin Point Laboratories COGS-to-Revenue Chart

Caplin Point Laboratories Annual Data

Trend

Jun15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

COGS-to-Revenue

Get a 7-Day Free Trial

0.49

0.45

0.44

0.46

0.43

Caplin Point Laboratories Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
COGS-to-Revenue	Get a 7-Day Free Trial															0.45	0.40	0.44	0.45	0.40

Caplin Point Laboratories COGS-to-Revenue Calculation

Caplin Point Laboratories's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	7293.4	/	16767.8
	=	0.43

Caplin Point Laboratories's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1854.8	/	4589.6
	=	0.40

Caplin Point Laboratories (BOM:524742) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Caplin Point Laboratories's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1854.8 / 4589.6
	=	59.59 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Caplin Point Laboratories COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Caplin Point Laboratories's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Caplin Point Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Caplin Point Laboratories Ltd (BOM:524742) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

CAPLIPOINT:India

Address

Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096

Website

https://www.caplinpoint.net

Caplin Point Laboratories Ltd is the India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, liquid orals, dry powder, soft gels, penems injections, suppositories. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops. The business of the company is organized into the following product segments, Antibiotics, Nsaids, Ophthalmics, Pain Management, and Antiulcers. Its products have a presence in the Latin American and African markets.

Caplin Point Laboratories Headlines

No Headlines